Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia.

Ramsay AJ, Quesada V, Foronda M, Conde L, Martínez-Trillos A, Villamor N, Rodríguez D, Kwarciak A, Garabaya C, Gallardo M, López-Guerra M, López-Guillermo A, Puente XS, Blasco MA, Campo E, López-Otín C.

Nat Genet. 2013 May;45(5):526-30. doi: 10.1038/ng.2584. Epub 2013 Mar 17.

PMID:
23502782
2.

Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.

Speedy HE, Kinnersley B, Chubb D, Broderick P, Law PJ, Litchfield K, Jayne S, Dyer MJS, Dearden C, Follows GA, Catovsky D, Houlston RS.

Blood. 2016 Nov 10;128(19):2319-2326. doi: 10.1182/blood-2016-01-695692. Epub 2016 Aug 15.

3.

Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis.

Gu P, Wang Y, Bisht KK, Wu L, Kukova L, Smith EM, Xiao Y, Bailey SM, Lei M, Nandakumar J, Chang S.

Oncogene. 2017 Apr 6;36(14):1939-1951. doi: 10.1038/onc.2016.405. Epub 2016 Nov 21.

4.

TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase.

Xin H, Liu D, Wan M, Safari A, Kim H, Sun W, O'Connor MS, Songyang Z.

Nature. 2007 Feb 1;445(7127):559-62. Epub 2007 Jan 21.

PMID:
17237767
5.

The OB-fold domain 1 of human POT1 recognizes both telomeric and non-telomeric DNA motifs.

Choi KH, Lakamp-Hawley AS, Kolar C, Yan Y, Borgstahl GEO, Ouellette MM.

Biochimie. 2015 Aug;115:17-27. doi: 10.1016/j.biochi.2015.04.015. Epub 2015 Apr 28.

6.

Cancer chromosomes going to POT1.

Chang S.

Nat Genet. 2013 May;45(5):473-5. doi: 10.1038/ng.2617.

7.

Structural and functional analysis of the human POT1-TPP1 telomeric complex.

Rice C, Shastrula PK, Kossenkov AV, Hills R, Baird DM, Showe LC, Doukov T, Janicki S, Skordalakes E.

Nat Commun. 2017 Apr 10;8:14928. doi: 10.1038/ncomms14928.

8.

PTOP interacts with POT1 and regulates its localization to telomeres.

Liu D, Safari A, O'Connor MS, Chan DW, Laegeler A, Qin J, Songyang Z.

Nat Cell Biol. 2004 Jul;6(7):673-80. Epub 2004 Jun 6.

PMID:
15181449
9.

Distinct requirements for Pot1 in limiting telomere length and maintaining chromosome stability.

Bunch JT, Bae NS, Leonardi J, Baumann P.

Mol Cell Biol. 2005 Jul;25(13):5567-78.

10.

Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation.

Augereau A, T'kint de Roodenbeke C, Simonet T, Bauwens S, Horard B, Callanan M, Leroux D, Jallades L, Salles G, Gilson E, Poncet D.

Blood. 2011 Aug 4;118(5):1316-22. doi: 10.1182/blood-2010-07-295774. Epub 2011 Feb 25.

11.

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.

Herling CD, Klaumünzer M, Rocha CK, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer KA.

Blood. 2016 Jul 21;128(3):395-404. doi: 10.1182/blood-2016-01-691550. Epub 2016 May 25.

12.

Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma.

Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, Ghiorzo P, Bressac-de Paillerets B, Nagore E, Avril MF, Caporaso NE, McMaster ML, Cullen M, Wang Z, Zhang X; NCI DCEG Cancer Sequencing Working Group; NCI DCEG Cancer Genomics Research Laboratory; French Familial Melanoma Study Group, Bruno W, Pastorino L, Queirolo P, Banuls-Roca J, Garcia-Casado Z, Vaysse A, Mohamdi H, Riazalhosseini Y, Foglio M, Jouenne F, Hua X, Hyland PL, Yin J, Vallabhaneni H, Chai W, Minghetti P, Pellegrini C, Ravichandran S, Eggermont A, Lathrop M, Peris K, Scarra GB, Landi G, Savage SA, Sampson JN, He J, Yeager M, Goldin LR, Demenais F, Chanock SJ, Tucker MA, Goldstein AM, Liu Y, Landi MT.

Nat Genet. 2014 May;46(5):482-6. doi: 10.1038/ng.2941. Epub 2014 Mar 30.

13.

Telomere status in chronic lymphocytic leukemia with TP53 disruption.

Guièze R, Pages M, Véronèse L, Combes P, Lemal R, Gay-Bellile M, Chauvet M, Callanan M, Kwiatkowski F, Pereira B, Vago P, Bay JO, Tournilhac O, Tchirkov A.

Oncotarget. 2016 Aug 30;7(35):56976-56985. doi: 10.18632/oncotarget.10927.

14.

Fission yeast Pot1-Tpp1 protects telomeres and regulates telomere length.

Miyoshi T, Kanoh J, Saito M, Ishikawa F.

Science. 2008 Jun 6;320(5881):1341-4. doi: 10.1126/science.1154819.

15.

Coordinated interactions of multiple POT1-TPP1 proteins with telomere DNA.

Corriveau M, Mullins MR, Baus D, Harris ME, Taylor DJ.

J Biol Chem. 2013 Jun 7;288(23):16361-70. doi: 10.1074/jbc.M113.471896. Epub 2013 Apr 24.

16.

RPA and POT1: friends or foes at telomeres?

Flynn RL, Chang S, Zou L.

Cell Cycle. 2012 Feb 15;11(4):652-7. doi: 10.4161/cc.11.4.19061.

17.

POT1 and TRF2 cooperate to maintain telomeric integrity.

Yang Q, Zheng YL, Harris CC.

Mol Cell Biol. 2005 Feb;25(3):1070-80.

18.

Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia.

Poncet D, Belleville A, t'kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral H, Callet-Bauchu E, Salles G, Sabatier L, Delic J, Gilson E.

Blood. 2008 Feb 15;111(4):2388-91. Epub 2007 Dec 12.

19.

TERRA and hnRNPA1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA.

Flynn RL, Centore RC, O'Sullivan RJ, Rai R, Tse A, Songyang Z, Chang S, Karlseder J, Zou L.

Nature. 2011 Mar 24;471(7339):532-6. doi: 10.1038/nature09772. Epub 2011 Mar 13.

20.

In vivo stoichiometry of shelterin components.

Takai KK, Hooper S, Blackwood S, Gandhi R, de Lange T.

J Biol Chem. 2010 Jan 8;285(2):1457-67. doi: 10.1074/jbc.M109.038026. Epub 2009 Oct 28.

Supplemental Content

Support Center